Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19

Front Cardiovasc Med. 2020 Nov 30:7:562708. doi: 10.3389/fcvm.2020.562708. eCollection 2020.

Temistocles Diaz^{1

2}, Barry H Trachtenberg³, Samuel J K Abraham^{4

5

6}, Rao KosagiSharaf², Armando A Durant-Archibold^{2

7}

¹ Internal Medicine-Interventional Cardiology, Department of Cardiology, Punta Pacifica Hospital, Affiliate of John Hopkins Medicine International, Panama City, Panama.
² Biomedicine Research Unit, Center for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT Asociation of Public Interest), Panama City, Panama.
³ Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, United States.
⁴ Department of Surgery & Centre for Advancing Clinical Research (CACR), Yamanashi University, Chuo, Japan.
⁵ Edogawa Evolutionary Laboratory of Science (EELS), Edogawa Hospital, Tokyo, Japan.
⁶ The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India.
⁷ Department of Biochemistry, College of Natural, Exact Science and Technology, Universidad de Panama, Panama City, Panama.

No abstract available

Keywords: COVID-19; SARS-CoV-2; aspirin; molecular mechanisms; prevention of cardiovascular disease.